Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis

Nissen, Steven E.; Nicholls, Stephen J.; Sipahi, İlke; Libby, Peter; Raichlen, Joel S.; Ballantyne, Christie M.; Davignon, Jean; Erbel, Raimund; Fruchart, Jean Charles; Tardif, Jean‐Claude; Schoenhagen, Paul; Crowe, Tim; Cain, Valerie A.; Wolski, Kathy; Goormastic, Marlene; Tuzcu, E. Murat; Investigators, for the ASTEROID

doi:10.1001/jama.295.13.jpc60002

Cited by 1,808 publications

(1,139 citation statements)

References 26 publications

Supporting

Mentioning

1,035

Contrasting

Unclassified

Order By: Relevance

“…More recent studies have demonstrated that statins are similarly beneficial for the primary and secondary prevention of CVD [10,20,24] and that the relative risk reduction is similar even in patients with very low absolute CV risk [22]. These results are partially explained by intra-vascular ultrasound (IVUS) studies showing that intensive LDL-C lowering using statins can significantly slow, and even reverse, the progression of atherosclerotic plaques in people with coronary heart disease (CHD) [25,26]. Consequently, statins remain the first-line lipid-lowering strategy for the vast majority of people with CV risk, including those with T2D.…”

Section: Statins Are Safe and Effective For The Reduction Of CV Risk mentioning

confidence: 99%

The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice

Sattar¹,

Ginsberg

Ray

et al. 2014

Atherosclerosis Supplements

Self Cite

View full text Add to dashboard Cite

Reducing low-density lipoprotein cholesterol (LDL-C) levels using statins is associated with significant reductions in cardiovascular (CV) events in a wide range of patient populations. Although statins are generally considered to be safe, recent studies suggest they are associated with an increased risk of developing Type 2 diabetes (T2D). This led the US Food and Drug Administration (FDA) to change their labelling requirements for statins to include a warning about the possibility of increased blood sugar and HbA1c levels and the European Medicines Agency (EMA) to issue guidance on a small increased risk of T2D with the statin class. This review examines the evidence leading to these claims and provides practical guidance for primary care physicians on the use of statins in people with or at risk of developing T2D. Overall, evidence suggests that the benefits of statins for the reduction of CV risk far outweigh the risk of developing T2D, especially in individuals with higher CV risk. To reduce the risk of developing T2D, physicians should assess all patients for T2D risk prior to starting statin therapy, educate patients about their risks, and encourage risk-reduction through lifestyle changes. Whether some statins are more diabetogenic than others requires further study. Statin-treated patients at high risk of developing T2D should regularly be monitored for changes in blood glucose or HbA1c levels, and the risk of conversion from pre-diabetes to T2D should be reduced by intensifying lifestyle changes. Should a patient develop T2D during statin treatment, physicians should continue with statin therapy and manage T2D in accordance with relevant national guidelines.

show abstract

Section: Statins Are Safe and Effective For The Reduction Of CV Risk mentioning

confidence: 99%

The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice

Sattar¹,

Ginsberg

Ray

et al. 2014

Atherosclerosis Supplements

Self Cite

View full text Add to dashboard Cite

show abstract

“…Denn die Bestimmung der Atheromgröße als neuer Surrogatparameter für die Beurteilung von pharmakodynamischen Defekten hat wesentliche Bedeutung erlangt, nachdem die Entwicklung der Plaquebildung über einen größeren Zeitraum gezeigt hatte, dass nicht nur die Plaqueprogression, sondern auch die Plaqueregression bestimmt werden kann und eng mit der klinischen Symptomatik verbunden ist [8,9,10]. Damit eröffnet der intravaskuläre Ultraschall die Möglichkeit, früher zu erkennen, ob die Wirkung eines Medikaments nicht nur mit Veränderungen von Laborparametern, sondern auch mit einer positiven oder negativen Beeinflussung der koronaren Atherosklerose verbunden ist [11].…”

Section: Fortschritte Der Diagnostik Sind Die Treibende Kraft Für Dieunclassified

Fortschritte der Diagnostik sind die treibende Kraft für die Weiterentwicklung interventioneller Verfahren

Erbel

2011

Herz

View full text Add to dashboard Cite

“…They observed a plaque reduction of almost 30% by 12 weeks. A human trial of the most effective statin achieved about 6% [2]. The combinedtreatment approach showed a hint of additive effects.…”

mentioning

confidence: 99%

Slouching towards gene therapy for hypercholesterolemia

Luft

2011

J Mol Med

View full text Add to dashboard Cite

Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis

Abstract: ClinicalTrials.gov Identifier: NCT00240318.

Cited by 1,808 publications

References 26 publications

The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice

The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice

Fortschritte der Diagnostik sind die treibende Kraft für die Weiterentwicklung interventioneller Verfahren

Slouching towards gene therapy for hypercholesterolemia

Contact Info

Product

Resources

About